Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended 12 July 2024. In this episode: Q1’s top 10 drugs; Pfizer’s R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.

https://scrip.citeline.com/SC150587/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode, HBW chats with Michael Washburn, principal at Washburn Consulting, on how producers of single-use packaging subject to extended producer responsibility laws rolling out in Oregon, Colorado and California next year can tackle the tedious work of collecting data on packaging materials.

Improving Communication: The Relationship Between Biotech And Biopharma by Citeline

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

今回取り上げた記事はこちら

「US FDA’s Cell-Gene Therapy Office Head Wants Sponsors To Seek Out Meetings（ 邦題意訳：米国FDAの細胞遺伝子治療室長「もっと面談を」企業に求める理由は）」

 

（英語版）

https://pink.citeline.com/PS154749/US-FDAs-Cell-Gene-Therapy-Office-Head-Wants-Sponsors-To-Seek-Out-Meetings

※全文の閲覧には購読（有料）が必要です。

 

世界の製薬ビジネスメディアScrip（スクリップ）とは？

https://www.citeline.com/ja-jp/products-services/commercialization/scrip

Audio roundup of selected biopharma industry content from Scrip over the business week ended 5 July 2024. In this episode: US approval for Lilly’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai regains control of ADC from BMS; RSV vaccine developers hit by declining expectations; and an interview with Amgen’s Ian Thompson.

https://scrip.citeline.com/SC150550/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Joseph Haas, Mandy Jackson and Kevin Grogan discuss the biopharma dealmaking environment as we reach the midpoint of 2024. Haas reviews dealmaking data from the first six months of the year and discusses what experts expect in the months ahead. Jackson and Grogan talk about the industry mood coming out of the annual BIO conference in June and what they heard at the meeting.

In this episode of the In Vivo podcast, Billy Boyle, CEO of Owlstone Medical, discusses how his company is developing several breath biopsy products for use by clinicians, biopharma companies and researchers.

In Vivo Podcast Episode with Stefan Woxström by Citeline

Aspirin is celebrating its 125th anniversary this year. To find out what brand owner Bayer Consumer Health is doing to celebrate this occasion, and what it is doing to take the brand into the next 125 years, HBW Insight chats with the company’s senior vice president, Global Head Allergy, Cough/Cold, Pain and Heart Health, Reese Fitzpatrick, and head of R&D, North America and Therapeutics, Rachel Koontz. Already used for a variety conditions by consumers and patients across the world, the Aspirin brand has much more to offer, they argue, for example, in terms of digital self-care, with the firm working with British medtech firm Huma Therapeutics on a Heart Health Risk Assessment app that it currently markets in the US and Middle East. Aspirin also still has Rx-to-OTC switch potential, they reveal, for example in markets like Mexico where the brand is not already available without a prescription. And if that’s not enough, we also discuss Bayer’s extension of the Aspi brand into the naturals space, particularly in the cough and cold category in Europe.

Timestamps

2:25 – Introductions

3:30 – Aspirin’s 125th anniversary

5:50 – Aspirin’s brand longevity

14:15 – Challenges of self-care

25:20 – Digital self-care and chronic conditions

27:50 – Aspirin’s Rx-to-OTC switch potential

33:30 – Science and self-care

39:90 – Natural alternatives

44:15 – What’s next for Aspirin?

Audio roundup of selected biopharma industry content from Scrip over the business week ended 28 June 2024. In this episode: global CEO remuneration; another late-stage loss for Merck KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.

https://scrip.citeline.com/SC150517/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things